Complete financial analysis of Denali Capital Acquisition Corp. (DECA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Denali Capital Acquisition Corp., a leading company in the Shell Companies industry within the Financial Services sector.
You may be interested
- Golden Growers Cooperative (GGROU) Income Statement Analysis – Financial Results
- Vox Royalty Corp. (VOXR.TO) Income Statement Analysis – Financial Results
- Sreeleathers Limited (SREEL.BO) Income Statement Analysis – Financial Results
- Longzhou Group Co., Ltd. (002682.SZ) Income Statement Analysis – Financial Results
- IX Acquisition Corp. (IXAQ) Income Statement Analysis – Financial Results
Denali Capital Acquisition Corp. (DECA)
Industry: Shell Companies
Sector: Financial Services
About Denali Capital Acquisition Corp.
Denali Capital Acquisition Corp. focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or other business combination with one or more businesses or entities. It intends to complete a business combination with companies primarily operating in the technology, consumer, and hospitality sectors. The company was incorporated in 2022 and is based in New York, New York.
| Metric | 2023 | 2022 |
|---|---|---|
| Revenue | 0.00 | 0.00 |
| Cost of Revenue | 3.17M | 0.00 |
| Gross Profit | -3.17M | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 |
| SG&A | 3.17M | 1.64M |
| Other Expenses | 0.00 | 1.64M |
| Operating Expenses | 3.17M | 1.64M |
| Cost & Expenses | 3.17M | 1.64M |
| Interest Income | 0.00 | 1.22M |
| Interest Expense | 36.91K | 0.00 |
| Depreciation & Amortization | 3.84M | 1.64M |
| EBITDA | 669.45K | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% |
| Operating Income | -3.17M | -2.86M |
| Operating Income Ratio | 0.00% | 0.00% |
| Total Other Income/Expenses | 3.81M | 1.22M |
| Income Before Tax | 632.54K | -419.39K |
| Income Before Tax Ratio | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -1.22M |
| Net Income | 632.54K | 802.21K |
| Net Income Ratio | 0.00% | 0.00% |
| EPS | 0.06 | 0.07 |
| EPS Diluted | 0.06 | 0.07 |
| Weighted Avg Shares Out | 9.99M | 10.82M |
| Weighted Avg Shares Out (Dil) | 9.99M | 10.82M |
Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination
NEW YORK, NEW YORK, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Denali Capital Acquisition Corp. (NASDAQ: DECA) (the “Company”) announced today that it has deposited into the Company's trust account (the “Trust Account”) an aggregate of $15,063.74 to fund the one-month...
Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination
NEW YORK, NEW YORK, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Denali Capital Acquisition Corp. (NASDAQ: DECA) (the “Company”) announced today that it has deposited into the Company's trust account (the “Trust Account”) an aggregate of $15,063.74 to fund the one-month...
Semnur Pharmaceuticals to go public via SPAC merger with Denali Capital in $2.5 bln deal
Semnur Pharmaceuticals, a wholly owned subsidiary of Scilex Holding Company , will go public via a merger with special purpose acquisition company Denali Capital Acquisition Corp in a $2.5 billion deal, the companies said on Tuesday.
Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Announce Signing of a Merger Agreement for a proposed Business Combination, Providing for a Pre-Transaction Equity Value of Semnur of $2.5 Billion
PALO ALTO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Semnur Pharmaceuticals, Inc. (“Semnur”), a wholly owned subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the...
Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination
NEW YORK, NEW YORK, , Aug. 09, 2024 (GLOBE NEWSWIRE) -- Denali Capital Acquisition Corp. (NASDAQ: DECA) (the “Company”) announced today that it has deposited into the Company's trust account (the “Trust Account”) an aggregate of $15,063.74 to fund the...
Denali Capital Acquisition Corp. Announces Shareholder Approval of Extension of Deadline to Complete Business Combination
NEW YORK, NEW YORK, July 10, 2024 (GLOBE NEWSWIRE) -- Denali Capital Acquisition Corp. (NASDAQ: DECA) (the “Company”) announced today that the Company's shareholders voted in favor of approving amendments to the Company's amended and restated memorandum and articles of...
Semnur Pharmaceuticals to go public in SPAC deal of up to $2 billion with Denali Capital
Drug developer Semnur Pharmaceuticals said on Tuesday it has signed a letter of intent to go public through a merger with special purpose acquisition company Denali Capital Acquisition Corp in a pre-transaction equity deal valued at up to $2 billion.
Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Enter into a Letter of Intent for a Proposed Business Combination
PALO ALTO, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Semnur Pharmaceuticals, Inc. (“Semnur”), a wholly owned subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the...
Correction: Denali Capital Acquisition Corp. and Longevity Biomedical, Inc. Mutually Agreed to Terminate the Business Combination
NEW YORK, June 27, 2024 (GLOBE NEWSWIRE) -- Denali Capital Acquisition Corp. (NASDAQ: DECA) ("Denali" or the "Company") announced today that Denali and Longevity Biomedical, Inc. have mutually agreed to terminate their previously announced business combination agreement (the “Business Combination...
Denali Capital Acquisition Corp. and Longevity Biomedical, Inc. Mutually Agreed to Terminate the Business Combination
NEW YORK, June 27, 2024 (GLOBE NEWSWIRE) -- Denali Capital Acquisition Corp. (NASDAQ: DECA) ("Denali" or the "Company") announced today that Denali and Longevity Biomedical, Inc. have mutually agreed to terminate their previously announced business combination agreement (the “Business Combination...
Source: https://incomestatements.info
Category: Stock Reports